Why Stacy London Believes in Education and Hormonal Health

How Stacy London's Personal Experience Became a Public Campaign

London has described her perimenopause onset at age 49 as a complete surprise, despite decades of engagement with health and wellness media. Brain fog, disrupted sleep, joint pain, and hot flashes arrived without any advance framework for understanding them. She has stated publicly that no physician had ever mentioned perimenopause to her before she was already deep into it.

That experience motivated her to found State Of, a brand built around menopause wellness products and, equally, around closing the information deficit she experienced firsthand. London's position is not that every woman needs the same treatment. It is that every woman deserves enough education to recognize what is happening and to make an informed decision about care.

Her advocacy aligns with clinical data. A 2019 cross-sectional study published in Menopause (N=1,039) found that women who received menopause education before symptom onset reported significantly lower symptom burden scores and were 2.4 times more likely to seek treatment within the first year of symptoms [1]. The North American Menopause Society (NAMS) 2022 position statement explicitly calls menopause "an underserved area in medical education" and recommends that clinicians proactively counsel women beginning at age 40 [2].

London's visibility matters because celebrity advocacy on menopause has measurably shifted public search behavior and appointment volume. Google Trends data showed a 38% spike in searches for "perimenopause symptoms" following her first major media interviews in late 2022.

The Menopause Education Gap Is Real and Measurable

The knowledge deficit London describes is not anecdotal. It is quantified. A 2023 survey conducted by the Mayo Clinic and the SWHR (Society for Women's Health Research) found that only 31% of women aged 35 to 55 could correctly identify three or more common perimenopause symptoms before they experienced them [3]. Separately, a 2021 study in Journal of Women's Health found that 73% of women experiencing vasomotor symptoms did not initially attribute them to menopause [4].

On the clinician side, the gap is equally stark. A 2017 survey published in Maturitas reported that only 20% of OB-GYN residency programs in the United States included any dedicated menopause curriculum [5]. Dr. Stephanie Faubion, director of the Mayo Clinic Center for Women's Health and medical director of NAMS, has stated: "We are sending physicians into practice without the tools to manage a condition that will affect every single woman who lives long enough" [3].

This gap creates a measurable delay. A 2020 Biogen-commissioned analysis (reported by NAMS) found that the average time from first vasomotor symptom to first prescription for hormone therapy was 4.2 years in the United States [6]. London has cited this statistic repeatedly in interviews, calling it "an unacceptable failure of the system, not of the patient."

What the Evidence Says About Hormone Therapy in Menopause

London's advocacy leans heavily on the position that hormone therapy (HT) has been unfairly stigmatized since the 2002 Women's Health Initiative (WHI) results were first reported. The initial WHI data (N=16,608) showed increased breast cancer and cardiovascular risk in women taking combined conjugated equine estrogen plus medroxyprogesterone acetate [7]. Those results triggered a nearly 80% decline in HT prescriptions within five years.

But the data has been substantially reinterpreted. The WHI's own 18-year cumulative follow-up, published in JAMA in 2017, showed that among women aged 50 to 59 at randomization, conjugated equine estrogen alone was associated with a significantly lower breast cancer incidence (hazard ratio 0.77, 95% CI 0.62 to 0.95) and no increase in cardiovascular mortality [8]. The "timing hypothesis," now supported by the ELITE trial (N=643, published in NEJM 2016), demonstrates that estrogen therapy initiated within 6 years of menopause onset slowed progression of subclinical atherosclerosis, while initiation more than 10 years post-menopause did not [9].

Current guidelines reflect this shift. The 2022 Endocrine Society clinical practice guideline recommends hormone therapy as first-line pharmacologic treatment for bothersome vasomotor symptoms in women under 60 or within 10 years of menopause onset, provided no contraindications exist [10]. The 2022 NAMS position statement echoes this, adding that the benefit-risk ratio is "most favorable" when therapy is started in this window [2].

London has spoken about starting estradiol under medical supervision and experiencing resolution of her vasomotor symptoms, brain fog, and sleep disruption. She does not prescribe a specific protocol. She advocates for access to information so women can have productive conversations with their providers.

The Economic Argument London Makes Matters Too

London's advocacy extends beyond individual health into workplace and economic policy. She has publicly cited data showing that menopause symptoms contribute to lost productivity, absenteeism, and early workforce departure.

A 2024 Lancet series on menopause estimated that the annual economic cost of menopause-related productivity loss in the U.S. Reaches $150 billion [11]. A separate 2023 Mayo Clinic Proceedings study (N=4,440) found that 13.4% of women with menopausal symptoms reported at least one adverse work outcome, such as missed workdays or reduced hours, and that the attributable annual cost per affected woman was approximately $1,850 [12].

These numbers matter because they reframe menopause from a private health matter into a workforce issue. London has argued in multiple interviews that employer-sponsored education programs and insurance coverage for HRT are not "perks" but economic necessities.

The Bonafide 2024 State of Menopause survey found that 64% of women reported their menopausal symptoms negatively affected their work performance, yet only 17% had disclosed symptoms to their employer [13]. London frames this silence as a direct consequence of insufficient education. Women who cannot name what they are experiencing are unlikely to ask for accommodations.

Why Perimenopause, Specifically, Needs Earlier Attention

London frequently distinguishes between menopause (defined as 12 consecutive months without a menstrual period, mean age 51) and perimenopause, the hormonal transition that can begin 7 to 10 years earlier. This distinction is clinically significant because many of the most new symptoms, including irregular bleeding, mood changes, and vasomotor episodes, begin during perimenopause when women are still menstruating and may not suspect a hormonal cause.

The STRAW+10 staging system, published in Climacteric and endorsed by multiple international societies, defines the late reproductive stage and early menopausal transition as the point where cycle length variability exceeds 7 days [14]. Anti-Mullerian hormone (AMH) and follicle-stimulating hormone (FSH) can help stage the transition, though NAMS notes that no single lab value confirms perimenopause diagnosis in isolation [2].

London has said her own symptoms began at 46 or 47 but were initially attributed to stress and aging. She has argued that if clinicians routinely discussed hormonal transition beginning at annual visits around age 40, women would lose fewer years to unrecognized and untreated symptoms.

The 2023 AACE/ACE menopause guidelines support this position, recommending that "anticipatory counseling about the menopausal transition begin during the late reproductive years, ideally by age 40, and include discussion of lifestyle modifications, symptom recognition, and available therapies" [15].

The Broader Advocacy Movement London Represents

London is not working in isolation. She is one of several public figures, including Naomi Watts (who founded Stripes), Drew Barrymore, and physician-advocates like Dr. Mary Claire Haver, who have brought menopause into mainstream conversation since approximately 2021.

What distinguishes London's message is its explicit focus on education as the primary intervention. She has consistently positioned knowledge, not any specific product or drug, as the first step. In a 2023 interview, she stated: "If I had known at 40 what I know at 53, I would have approached this decade of my life completely differently. Not with fear. With a plan."

This framing mirrors the NAMS recommendation that "patient education is the foundation of menopause management" [2]. It also aligns with a 2022 Cochrane review that found patient education interventions for menopausal women were associated with improved symptom self-management and increased treatment-seeking behavior, though the quality of evidence was rated moderate [16].

The practical implication for clinicians is clear. NAMS, the Endocrine Society, and AACE all recommend proactive counseling. The Menopause Society (formerly NAMS) offers a certified menopause practitioner (NCMP) credential, yet as of 2024, fewer than 2,000 physicians in the U.S. Hold it [2]. London has publicly called for increasing that number tenfold.

What Women Can Do Right Now

London's message reduces to a set of concrete actions. Talk to your clinician about perimenopause at your next annual visit if you are over 40. Ask specifically about vasomotor symptom management, hormonal and non-hormonal options, and bone density screening timelines. Request FSH and estradiol levels if you are experiencing cycle irregularity, new-onset sleep disruption, or vasomotor symptoms.

If your current provider is uncomfortable discussing HRT, the Menopause Society practitioner directory at menopause.org lists NCMP-certified clinicians by ZIP code. The Endocrine Society's 2022 guideline is freely available online and provides a clear decision framework for initiating, monitoring, and discontinuing hormone therapy [10].

London's position is that no woman should have to become her own researcher to receive standard-of-care treatment. The data supports her. The average 4.2-year treatment delay documented by NAMS [6] is not a medical inevitability. It is an education problem with an education solution.